浙江省1~6岁健康儿童接种水痘减毒活疫苗后抗体水平研究
在浙江省衢州市和丽水市招募378名1~6岁健康儿童,接种1剂次水痘减毒活疫苗(人二倍体细胞SV-1株),接种后30天内不良事件总体发生率为6.61%。355名纳入免疫原性分析者免后总体阳转率为87.04%,总体几何平均滴度为23.14;免前抗体滴度与疫苗接种史是免后抗体滴度的正相关因素。血清学证据提示仅接种1剂次后VZV-IgG抗体衰减较快,需及时加强免疫。
要点
- 1~6岁儿童接种水痘疫苗后总体不良事件发生率为6.61%。
- 免后总体阳转率87.04%,总体几何平均滴度23.14。
- 免前抗体滴度与接种史是免后抗体滴度的正相关因素。
核心结论
- 基于人二倍体细胞SV-1株的水痘疫苗在1~6岁儿童中安全性和免疫原性较好。
- 仅接种1剂次后VZV-IgG抗体衰减较快,需及时开展加强免疫。
研究设计与样本
- 在浙江省衢州市及丽水市招募1~6岁健康儿童378名,均完成1剂次水痘减毒活疫苗接种。
- 分为1~3岁无接种史组、4~6岁无接种史组和4~6岁有1剂次接种史组。
- 接种前及接种后30~35天采集血清,用FAMA法检测VZV-IgG抗体,评价接种后30天内不良事件。
- 355名受试者纳入免疫原性分析,采用多元线性逐步回归探索免后GMT相关因素。
主要发现
- 总体不良事件报告发生率为6.61%,4~6岁组初次免疫与加强免疫后不良事件发生率差异无统计学意义(6.67% vs. 6.77%,χ2<0.001,P>0.999)。
- 有接种史的4~6岁组免前SPR仅为18.64%。
- 1~6岁儿童免后总体SCR为87.04%,免后总体GMT为23.14。
- 1~3岁组、4~6岁无接种史组和有接种史组免后GMT依次为22.04、15.81和27.15。
- 免前抗体滴度(标准化β=0.58,P<0.001)与水痘疫苗接种史(1剂 vs. 0剂:标准化β=0.11,P=0.011)是免后抗体滴度的正相关因素。
临床怎么用
- 对1~6岁儿童接种水痘减毒活疫苗时关注不良事件监测,总体发生率6.61%。
- 重视仅接种1剂次后抗体衰减较快的血清学证据,及时开展加强免疫。
- 评估免后抗体水平时可参考免前抗体滴度和疫苗接种史等正相关因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the safety and immunogenicity of a live attenuated varicella vaccine and to explore factors influencing post-vaccination varicella-zoster virus (VZV) antibody levels in healthy children aged 1-6 years in Zhejiang Province. Methods: A total of 378 healthy children aged 1-6 years were enrolled from Quzhou and Lishui in Zhejiang Province and categorized into three groups: 1-3-year-olds without prior vaccination, 4-6-year-olds without prior vaccination, and 4-6-year-olds with one prior dose of vaccination. All participants received one dose of live attenuated varicella vaccine. Serum samples were collected before and 30-35 days after vaccination, and VZV-IgG antibodies were detected using the fluorescent antibody to membrane antigen (FAMA) assay. The incidence of adverse events (AEs) within 30 days post-vaccination was assessed. Geometric mean titers (GMT), seroconversion rates (SCR), and seropositive rates (SPR) of VZV-IgG antibodies were analyzed before and after vaccination. The multiple linear stepwise regression was used to explore factors influencing post-vaccination GMT. Results: All 378 enrolled participants completed vaccination. The overall incidence of AEs was 6.61%, with no significant difference between the primary and booster immunization groups in 4-6-year-olds (6.67% vs. 6.77%, χ2<0.001, P>0.999). Among 355 participants included in the immunogenicity analysis, the pre-vaccination SPR in the 4-6-year-old group with a vaccination history was only 18.64%. The overall SCR after vaccination in children aged 1-6 years was 87.04%, and the overall GMT was 23.14, with GMTs of 22.04, 15.81, and 27.15 in the unvaccinated 1-3-year-olds, unvaccinated 4-6-year-olds, and previously vaccinated 4-6-year-olds, respectively. Multiple linear stepwise regression revealed that pre-vaccination antibody titer (standardized β=0.58, P<0.001) and prior varicella vaccination history (1 dose vs. 0 dose: standardized β=0.11, P=0.011) were positively associated with post-vaccination antibody titer. Focusing on the 4-6-year-old booster group, regression analysis indicated that post-vaccination antibody titer was positively associated with pre-vaccination antibody titer (standardized β=0.60, P<0.001), and participants from Liandu District had higher antibody titers than those from Jiangshan City (standardized β=0.16, P=0.007). Conclusion: The varicella vaccine (human diploid cell SV-1 strain) demonstrates favorable safety and immunogenicity in children aged 1-6 years. Serological evidence indicates a relatively rapid decline in VZV-IgG antibody levels after a single dose, highlighting the need for timely administration of a booster immunization. 目的: 评价浙江省1~6岁健康儿童接种水痘减毒活疫苗后的安全性及免疫原性,探索其免后水痘-带状疱疹病毒(VZV)抗体水平的影响因素。 方法: 在浙江省衢州市及丽水市招募1~6岁健康儿童,将研究对象分为1~3岁无接种史组,4~6岁无接种史组和4~6岁有1剂次接种史组,接种1剂次水痘减毒活疫苗(人二倍体细胞SV-1株),分别在其接种疫苗前及接种疫苗后30~35 d各采集1份血清标本,采用膜抗原荧光抗体法(FAMA法)检测水痘-带状疱疹病毒IgG抗体(VZV-IgG),评价其接种后30 d内不良事件发生率,分析接种前后VZV-IgG抗体几何平均滴度(GMT)、阳转率(SCR)及阳性率(SPR),基于多元线性逐步回归探索其免后GMT的相关因素。 结果: 共纳入378名研究对象,378名均完成疫苗接种,总体不良事件报告发生率为6.61%,4~6岁组中初次免疫(6.67%)和加强免疫后不良事件发生率(6.77%)差异无统计学意义(χ2<0.001,P>0.999)。355名受试者纳入免疫原性分析,有接种史的4~6岁组免前SPR仅为18.64%;1~6岁儿童免后总体SCR为87.04%,免后总体GMT为23.14,1~3岁组、4~6岁无接种史组和有接种史组的免后GMT依次为22.04、15.81和27.15。多元线性逐步回归显示:免前抗体滴度(标准化 β=0.58,P<0.001)与水痘疫苗接种史(1剂 vs. 0剂:标准化 β=0.11,P=0.011)是免后抗体滴度的正相关因素。聚焦有接种史的4~6岁组,多元线性逐步回归分析显示免后抗体滴度与免前抗体滴度正相关(标准化 β=0.60,P<0.001),且莲都区受试者的免后抗体滴度高于江山市(标准化 β=0.16,P=0.007)。 结论: 基于人二倍体细胞SV-1株的水痘疫苗在1~6岁儿童中展现出较好的安全性和免疫原性,血清学证据显示仅接种1剂次水痘疫苗后的VZV-IgG抗体衰减速率较快,需及时开展水痘疫苗加强免疫。.
引用
- Deng X, Luo F, He HQ, et al. [Antibody levels of healthy children aged 1-6 years old vaccinated with live attenuated varicella vaccine in Zhejiang Province]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026. PMID: 41606973. doi:10.3760/cma.j.cn112150-20250731-00738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。